Leonel Reyes, MD
Family Medicine · San Antonio, TXNPI 1841302049
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.3%. 2025 is the largest year on record at $3,306, 8.6 times the $382 reported in 2019. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $63.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Biogen$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Janssen Research & Development, LLC$1K
- Novartis$1K
- Modernatx, Inc.$943
- plus $2K from 13 others
Across 488 payments — averaging $8799.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Sanofi Pasteur Inc.$933K
- Modernatx, Inc.$471K
- AbbVie$449K
- AstraZeneca$381K
- Novartis$163K
- plus $678K from 12 others
What the payments were for
- Travel & lodging$4,77549%
- Food & beverage$4,95651%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $1,878 |
| Biogen | 8 | $1,517 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $1,164 |
| Janssen Research & Development, LLC | 9 | $1,139 |
| Novartis | 6 | $1,041 |
| Modernatx, Inc. | 8 | $943 |
| AbbVie(2 entities) | 41 | $622 |
| AstraZeneca | 6 | $445 |
| Alkermes, Inc. | 2 | $208 |
| Teva Pharmaceuticals USA, Inc. | 2 | $146 |
| Lilly USA, LLC | 5 | $131 |
| Amgen | 1 | $122 |
| Intuity Medical Inc | 1 | $115 |
| Genentech, Inc. | 1 | $103 |
| Abbott | 1 | $86 |
| Exact Sciences | 2 | $37 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$490
- CAPLYTA$378
- FARXIGA$250
- VRAYLAR$202
- Austedo XR$128
- ENTRESTO$122
- Otezla$122
- Pogo Automatic Blood Glucose Monitoring System$115
- Xofluza$103
How this compares
$9,749 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 61 | $42,571 |
| TradjentaLinagliptin | 44 | $30,865 |
| LinzessLinaclotide | 41 | $29,460 |
| JardianceEmpagliflozin | 36 | $27,990 |
| MounjaroTirzepatide | 22 | $23,952 |
| MyrbetriqMirabegron | 16 | $7,021 |
| Atomoxetine Hcl | 14 | $2,621 |
| Tramadol Hcl | 227 | $2,401 |
| Alprazolam | 127 | $1,575 |
| Insulin Glargine-Yfgn | 13 | $1,513 |
| Quetiapine Fumarate | 30 | $1,196 |
| Gabapentin | 63 | $1,048 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $928 |
| Clorazepate Dipotassium | 14 | $895 |
| Atorvastatin Calcium | 108 | $685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $13 | $42,57161 claims |
| AbbVieLinzess | $622 | $29,46041 claims |
| Lilly USA, LLCMounjaro | $131 | $23,95222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Aaron KingSan Antonio$1.1M
- Solomon PaleySan Antonio$136K
- Sarah SamreenSan Antonio$133K
- Melissa WalkerSan Antonio$53K
- Paul SaenzSan Antonio$50K
- Carlos CamposNew Braunfels$1.5M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.